Ann: First Patient Enrolled in Cynata MEND Clinical Trial, page-2

Key highlights

• First patient with respiratory failure enrolled in Cynata’s MEND clinical trial

• Trial to investigate early efficacy of Cynata’s Cymerus™ mesenchymal stem cells (MSCs) in
patients with respiratory failure, who meet the well-established criteria for Acute Respiratory
Distress Syndrome (ARDS)

• Respiratory failure/distress (including ARDS) is a severe and life-threatening illness, representing
a major unmet medical need

• Trial cements Cynata’s world-leading position in the development of next generation
commercially scalable stem cell products

Dr. Kilian Kelly, Cynata’s COO, said:
“Commencing this clinical trial is a major milestone for Cynata and our proprietary Cymerus MSC technology.
The trial will allow us to investigate the potential benefits our MSCs could have in the treatment of these
severely ill patients in dire need.

Our proprietary Cymerus manufacturing platform, which utilises an induced pluripotent stem cell (iPSC) bank sourced from a single blood donation from one donor, eliminates the reliance upon multiple donors and the need to excessively expand MSCs derived from them. Cynata is truly at the forefront of the industry with a sustainable and scalable manufacturing process for therapeutic MCS products.”

A total of 24 adult patients are expected to participate in the trial being conducted at centres in New South Wales and Victoria in collaboration with the Cerebral Palsy Alliance Research Institute and investigators from the COVID-19 Stem Cell Treatment (CSCT) Group.

The study is an open-label, randomised controlled clinical trial to investigate early efficacy of Cymerus MSCs in patients admitted to intensive care with respiratory distress. Twelve patients will be randomised to receive Cymerus MSC infusions, in addition to standard of care, while 12 patients will be randomised to the control group and will receive current standard of care only. The primary efficacy endpoint will be trajectory of PaO2/FiO2 ratio (a measure of hypoxemia, a low level of oxygen in the blood caused by compromised lung function) by Day 7. Safety and tolerability up to Day 28 will also be a primary endpoint.

Results from the trial could demonstrate potential relevance in several diseases including ARDS, Cytokine Release Syndrome (CRS) and sepsis.

Respiratory failure or distress (including ARDS) is a severe and life-threatening illness, representing a major unmet medical need. ARDS is an inflammatory process leading to build-up of fluid in the lungs due to infection, trauma and inhalation of noxious substances, with no specific pharmacological treatment options currently available. ARDS accounts for 10% of all ICU admissions and ~25% of patients require mechanical ventilation, with hospital mortality up to 46%

The combined market opportunity of ARDS, together with CRS and Sepsis, is estimated to be over US$8 billion.